TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients
TROPHIT1 是一项随机、开放标签、多中心 II/III 期临床试验,旨在比较 sacituzumab govitecan 与转移性结直肠癌患者的标准治疗方案。
期刊:
影响因子:
doi:10.1016/j.esmogo.2024.100118
Köhler, B C; Haag, G M; Le Cornet, L; Hoffmeister-Wittmann, P; Schmidt, M; Manjunath, A; Vaquero-Siguero, N; Jenzer, M; Gimmel, M; Stahler, A; Stein, A; Reichert, M; Kasper, S; Bitzer, M; Jäger, D; Springfeld, C; Weber, T F; Fröhling, S; Steindorf, K; Trumpp, A; Schlenk, R F; Jackstadt, R